Your Company has, over the years, been known for its trend setting
standards in the Indian pharmaceutical market. All along it has offered
innovative dosage forms at affordable prices, especially in the
segments of ophthalmias, pediatrics, infant diarrhoea, lactose
intolerance, and dermatologicals. Moreover, in the last 5 years, its
anti-infective range of Cephalosporin dosage forms have achieved
prominent ORG rankings by gaining substantial market share and brand
equity in record time.
Being the first Indian Company to get the U.K. MHRA approval to
manufacture sterile ophthalmic dosage forms in India, FDC has garnered
significant market share in the U.K., for its ophthalmic range
anti-infectives, anti-glaucoma, and viscolizers. Soon your Company will
get regulatory clearances for a few more ophthalmic products in the
U.K., including an anti-allergic and a new anti-glaucoma dosage form.
Similar marketing authorizations are expected, and will result in
meaningful revenues from other countries in the European Union.
With the approval of the ANVISA (Brazilian Regulatory Authority), our
ophthalmic facility at Waluj will shortly begin to supply ophthalmias
to the Brazilian market with a long-term objective to cater to many
more Latin American countries. In addition, our launch of ophthalmics
in the U.S. is in its final stage. With six ANDA's near approval, we
are exploring marketing options in the U.S.
With the Patent regime in place, you will be pleased to note that your
Company has collaborated with renowned ophthalmologists to develop a
novel single-dose unit (UNIMS), which was launched in India in June
2006. Apart from patenting and marketing this product in India, this
product will soon be marketed worldwide, after we comply with the
Regulatory requirements of various countries.
As a progressive Company, FDC is making efforts to develop New Chemical
Entities (NCE's). As a result, a number of new structures in the field
of anti-fungals are at various stages of evaluation. Few of these
structures will be patentable as well as valuable. Moreover, we have
developed in-house capabilities to perform studies on the
anti-bacterial activities of these compounds.
Our new State-of-the-art facility to manufacture Cephalosporin dosage
forms at Baddi, Himachal Pradesh, will commence operations in July
2006. This facility is built on a global scale, and is geared to meet
international quality standards.
Your Company's biotechnology R&D scientists have developed, in-house,
various mammalian cell lines, which will help us to screen new
molecules in the field of ophthalmology, further strengthening our
By leveraging the following strengths:
1. Well established brands in several segments
2. Many leading brands in the ORS, Ophthalmic, and anti-infective
3. World-class, state-of-the-art manufacturing facilities
4. Regulatory expertise to consistently meet with the standards of the
most stringent regulatory bodies U.S. FDA, U.K. MKHRA, SA MCC, ANVISA,
5. Cost-effective and innovative products
6. Cutting-edge R& D infrastructure
We expect to grow steadily in the year 2006-2007.
I take this opportunity to thank you all our shareowners, the medical
fraternity, the consumers, our suppliers, our valuable employees and
the public at large. Thank you for your support, trust and confidence
in us - year after year!
MOHAN A. CHANDAVARKAR
Chairman and Managing Director
June 24, 2006